Calidi Biotherapeutics, Inc. (CLDI): auditor change — Calidi Biotherapeutics replaces auditor Marcum with CBIZ after Marcum acquisition

Calidi Biotherapeutics, Inc.

Marcum resigned as independent auditor on April 30, 2025, following its acquisition by CBIZ.
Audit Committee approved CBIZ as new auditor for fiscal year ending December 31, 2025.
Marcum's reports for 2023 and 2024 included a going concern explanatory paragraph; no adverse opinions.
No disagreements or reportable events between the company and Marcum during the past two fiscal years.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Marcum LLP resigned as auditor of Calidi Biotherapeutics, Inc..

Action: resignation
Auditor: Marcum LLP
Successor: CBIZ CPAs P.C.

Exact text from the filing

On April 30, 2025, as a result of the acquisition, Marcum resigned as the independent registered public accounting firm of Calidi Biotherapeutics, Inc.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Calidi Biotherapeutics, Inc. engaged CBIZ CPAs P.C. as its auditor.

Action: engagement
Auditor: CBIZ CPAs P.C.

Exact text from the filing

ovember 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum LLP (“Marcum”), and substantially all of the partners and staff that provided attestation services with Marcum joined CBIZ in connection with the acquisition. Accordingly, on April 30, 2025, as a result of the acquisition, Marcum resigned as the independent registered public accounting firm of Calidi Biotherapeutics, Inc. (the “Company”) and, on April 30, 2025, the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) approved the appointment of CBIZ as the Company’s independent registered public accounting firm. The reports of Marcum on the Company’s consolidated financial statements for the years ended December 31, 2024, and December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting

View on SEC.gov

Browse all auditor changes →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-008365

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.